TARO PHARMACEUTICAL INDUSTRIES LTD
DelistedCIK 906338fmd_0AD4ZM7V0TTABS8GVN0VAAE3FAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Mar 31, 2023, 16 periods
Latest annual · FY2023
Millions- Total revenues
- 573
- Gross profit
- 268
- Operating income
- 18
- Net income
- 25
- Free cash flow
- 14
Latest quarter · Q4 FY2012
Millions- Total revenues
- 145
- Gross profit
- 99
- Operating income
- 66
- Net income
- 47
- Free cash flow
- 76
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- -3.9%
- Revenue, 5 yearsFY2018 to FY2023
- -2.8%
- Net income, 5 yearsFY2018 to FY2023
- -34.5%
TARO PHARMACEUTICAL INDUSTRIES LTD financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $573 million | $561.3 million | +2.1% | 20-F 2023-06-29 · proof |
| Gross profit | $268.3 million | $293.1 million | -8.5% | 20-F 2023-06-29 · proof |
| Operating income | $17.7 million | $63.5 million | -72.1% | 20-F 2023-06-29 · proof |
| Net income | $25.4 million | $58.3 million | -56.3% | 20-F 2023-06-29 · proof |
| Cash from operating activities | $31.8 million | -$158.7 million | 20-F 2023-06-29 · proof | |
| Free cash flow | $14.2 million | -$170.5 million | 20-F 2023-06-29 · proof | |
| Total assets | $2.1 billion | $2.2 billion | -1.9% | 20-F 2023-06-29 · proof |
| Total liabilities | $404.7 million | $464.9 million | -13% | 20-F 2023-06-29 · proof |
| Cash and cash equivalents | $154.5 million | $251.1 million | -38.5% | 20-F 2023-06-29 · proof |
- What was TARO PHARMACEUTICAL INDUSTRIES LTD's revenue in fiscal 2023?
- TARO PHARMACEUTICAL INDUSTRIES LTD reported revenue of $573 million for fiscal 2023 (the year ended Mar 31, 2023), against $561.3 million the year before (+2.1%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What was TARO PHARMACEUTICAL INDUSTRIES LTD's gross profit in fiscal 2023?
- TARO PHARMACEUTICAL INDUSTRIES LTD reported gross profit of $268.3 million for fiscal 2023 (the year ended Mar 31, 2023), against $293.1 million the year before (-8.5%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What was TARO PHARMACEUTICAL INDUSTRIES LTD's operating income in fiscal 2023?
- TARO PHARMACEUTICAL INDUSTRIES LTD reported operating income of $17.7 million for fiscal 2023 (the year ended Mar 31, 2023), against $63.5 million the year before (-72.1%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What was TARO PHARMACEUTICAL INDUSTRIES LTD's net income in fiscal 2023?
- TARO PHARMACEUTICAL INDUSTRIES LTD reported net income of $25.4 million for fiscal 2023 (the year ended Mar 31, 2023), against $58.3 million the year before (-56.3%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What was TARO PHARMACEUTICAL INDUSTRIES LTD's cash from operating activities in fiscal 2023?
- TARO PHARMACEUTICAL INDUSTRIES LTD reported cash from operating activities of $31.8 million for fiscal 2023 (the year ended Mar 31, 2023), against -$158.7 million the year before. Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What was TARO PHARMACEUTICAL INDUSTRIES LTD's free cash flow in fiscal 2023?
- TARO PHARMACEUTICAL INDUSTRIES LTD reported free cash flow of $14.2 million for fiscal 2023 (the year ended Mar 31, 2023), against -$170.5 million the year before. Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What are TARO PHARMACEUTICAL INDUSTRIES LTD's total assets?
- As of Mar 31, 2023, TARO PHARMACEUTICAL INDUSTRIES LTD reported total assets of $2.1 billion, against $2.2 billion a year earlier (-1.9%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What are TARO PHARMACEUTICAL INDUSTRIES LTD's total liabilities?
- As of Mar 31, 2023, TARO PHARMACEUTICAL INDUSTRIES LTD reported total liabilities of $404.7 million, against $464.9 million a year earlier (-13%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
- What are TARO PHARMACEUTICAL INDUSTRIES LTD's cash and cash equivalents?
- As of Mar 31, 2023, TARO PHARMACEUTICAL INDUSTRIES LTD reported cash and cash equivalents of $154.5 million, against $251.1 million a year earlier (-38.5%). Source: the 20-F filed with the SEC on Jun 29, 2023. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:906338&period_type=annual&limit=5"Information only, not investment advice.